Protagonist Q2 2022 Earnings Report
Key Takeaways
Protagonist Therapeutics reported their Q2 2022 financial results, highlighting the continued progress of the Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) and a strong cash position with runway through the end of 2024. The company is also advancing other programs, including PN-235 with Janssen and PN-943, while engaging with regulators for guidance on further clinical development.
Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV).
Presented new, positive data from Phase 2 REVIVE study of rusfertide in PV.
Janssen is pursuing multiple clinical studies of PN-235, including two Phase 2 studies in moderate-to-severe plaque psoriasis.
Cash position remains strong, with runway through the end of 2024.
Protagonist
Protagonist
Forward Guidance
The company provided forward-looking statements regarding plans to secure a collaborative partner to support further clinical development of PN-943, the clinical development of rusfertide and expectations regarding clinical trial enrollment, expected cash runway and potential milestones related to PN-235.